Filing Flows

Filing Flows › ImmunityBio (IBRX) › How it makes money

How ImmunityBio (IBRX) makes money

ImmunityBio (IBRX) made $51.2M of revenue in the second quarter 2026 (Q2 2026), +94% from a year earlier. Product revenue, net brought in $50.7M (99%); Other revenues brought in $568K (1%).

Drawing the Sankey…

ImmunityBio revenue by segment, Q2 2026ImmunityBio revenue by segment, Q2 2026Product revenue, net$50.7MOther revenues$568K
ImmunityBio: revenue by line, Q4 2024 to Q2 2026ImmunityBio: revenue by line, Q4 2024 to Q2 2026Product revenue, netOther revenuesProduct revenue, net: $50.7M latest$50.7MOther revenues: $568K latestQ4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Other revenues went from 5% of revenue in Q4 2024 to 1% in Q2 2026, the largest shift in the mix.
ImmunityBio revenue by quarterImmunityBio revenue by quarter$7.6MQ4 2024$16.5MQ1 2025$26.4MQ2 2025$32.1MQ3 2025$38.3MQ4 2025$44.2MQ1 2026$51.2MQ2 2026

Revenue by segment, Q2 2026

SegmentRevenueShareQ/QY/Y
Product revenue, net$50.7M98.9%+15%+92%
Other revenues$568K1.1%15×142×

Where each dollar of revenue goes

LineQ2 2026% of revenue
Revenue$51.2M100.0%

Revenue, quarter by quarter

QuarterRevenueY/Y
Q2 2026$51.2M+94%
Q1 2026$44.2M+168%
Q4 2025$38.3M+407%
Q3 2025$32.1M+425%
Q2 2025$26.4M25×
Q1 2025$16.5M413×
Q4 2024$7.6M54×

From ImmunityBio's 10-Q filed Aug 4, 2026 (on EDGAR).

Questions

How does ImmunityBio make money?

ImmunityBio (IBRX) made $51.2M of revenue in the second quarter 2026 (Q2 2026), +94% from a year earlier. Product revenue, net brought in $50.7M (99%); Other revenues brought in $568K (1%).

What is ImmunityBio's biggest business?

Product revenue, net: $50.7M in the second quarter 2026, 99% of revenue, +92% from a year earlier.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.